William Blair Has Optimistic Outlook of ELAN Q1 Earnings

Elanco Animal Health Incorporated (NYSE:ELAN) – Equities researchers at William Blair boosted their Q1 2025 earnings estimates for shares of Elanco Animal Health in a report issued on Tuesday, February 25th. William Blair analyst B. Vazquez now forecasts that the company will earn $0.32 per share for the quarter, up from their prior forecast of $0.30. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same quarter last year, the company earned $0.08 earnings per share. Elanco Animal Health’s quarterly revenue was down 1.4% compared to the same quarter last year.

A number of other brokerages also recently commented on ELAN. Leerink Partners began coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They issued a “market perform” rating and a $14.00 price objective on the stock. Leerink Partnrs raised shares of Elanco Animal Health to a “hold” rating in a research report on Monday, December 2nd. UBS Group lowered their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday. Morgan Stanley reduced their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a research note on Wednesday. Finally, Stifel Nicolaus reduced their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Friday, February 21st. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, Elanco Animal Health has a consensus rating of “Hold” and a consensus target price of $15.83.

Elanco Animal Health Trading Up 2.4 %

Shares of NYSE:ELAN opened at $11.19 on Friday. Elanco Animal Health has a 52 week low of $10.20 and a 52 week high of $18.80. The company’s 50 day moving average is $11.71 and its two-hundred day moving average is $13.03. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The company has a market cap of $5.53 billion, a PE ratio of 27.96, a P/E/G ratio of 2.50 and a beta of 1.42.

Institutional Trading of Elanco Animal Health

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AM Squared Ltd acquired a new stake in shares of Elanco Animal Health in the third quarter valued at about $34,000. Wilmington Savings Fund Society FSB acquired a new position in Elanco Animal Health during the third quarter worth about $35,000. CoreCap Advisors LLC acquired a new position in Elanco Animal Health during the fourth quarter worth about $29,000. Farther Finance Advisors LLC raised its position in Elanco Animal Health by 158.7% during the third quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock worth $49,000 after acquiring an additional 2,044 shares during the last quarter. Finally, Venturi Wealth Management LLC raised its position in Elanco Animal Health by 89.9% during the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock worth $50,000 after acquiring an additional 1,601 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.